Delcath Systems, INC Form 4 insider transactions

Director Gil Aharon converted warrants into common stock and pre-funded warrants of Delcath Systems, Inc.

Rosalind Advisors, Inc., along with related individuals, acquired Delcath Systems common shares and pre-funded warrants through the conversion of existing warrants.

Director Aharon Gil reports a transaction involving Delcath Systems' securities, including warrants and convertible notes.

Director Steven Salamon reports a transaction involving Delcath Systems' warrants and convertible notes, including the repayment of an 8% convertible note with $1,423,333 in cash.

Rosalind Advisors, along with directors Steven Salamon and Gil Aharon, report transactions related to Delcath Systems, including warrant exercises and convertible note repayments.

Delcath Systems CEO Gerard Michel exercised warrants and disposed of 16,666 shares of common stock on October 22, 2024.

Director Elizabeth Czerepak received stock options to purchase 22,500 shares of Delcath Systems common stock.

Director John Richard Sylvester acquired 22,500 stock options in Delcath Systems, Inc. on May 23, 2024.

Director Steven Salamon acquired stock options in Delcath Systems, Inc. on May 23, 2024.

Director Aharon Gil reports the acquisition of stock options in Delcath Systems, Inc.

Director Bridget A. Martell acquired 22,500 stock options in Delcath Systems, Inc. on May 23, 2024.

Roger G. Stoll, a director at Delcath Systems, amended several stock option grants to extend the post-termination exercise period.

Director Aharon Gil reports acquiring common shares of Delcath Systems through warrant exercise and preferred share conversion, as detailed in a Form 4/A filing.

Director Steven Salamon reports acquisition of common shares through warrant exercise and preferred share conversion, resulting in a maintained beneficial ownership.

Rosalind Advisors, Inc. reports acquiring Delcath Systems shares through the exercise of pre-funded warrants and conversion of preferred shares, as indicated in a Form 4/A filing.

Director Aharon Gil reports acquiring common shares of Delcath Systems through the exercise of pre-funded warrants and conversion of preferred shares.

Director Steven Salamon reports acquiring common shares of Delcath Systems through preferred share conversion and warrant exercise.

Rosalind Advisors, Inc., along with directors Steven Salamon and Gil Aharon, report acquiring Delcath Systems shares through warrant exercise and preferred share conversion, increasing their holdings.

Director Gil Aharon of Delcath Systems, Inc. reports purchasing 26,882 shares of common stock at $3.72 per share on March 19, 2024.

Director Steven Salamon purchased 26,882 shares of Delcath Systems at $3.72 per share on March 19, 2024, increasing his total holdings to 1,121,025 shares.

Rosalind Advisors, Inc. reports acquisition of pre-funded warrants in Delcath Systems, Inc., along with related beneficial ownership details.

Martha S. Rook, Chief Operating Officer of Delcath Systems, Inc., reports the acquisition of 125,000 employee stock options on March 18, 2024.

Vojo Vukovic, Chief Medical Officer of Delcath Systems, Inc., acquired 26,882 shares of common stock on March 19, 2024.

Gerard J. Michel, CEO of Delcath Systems, Inc., acquired 40,323 shares of common stock at a price of $3.72 on March 19, 2024.

Sandra Pennell, SVP of Finance, PFO, and PAO of Delcath Systems, Inc., acquired 26,881 shares of common stock at $3.72 per share on March 19, 2024, increasing her total holdings to 61,052 shares.

Kevin Muir, GM of Interventional Oncology at Delcath Systems, reports acquiring 13,441 shares of common stock through the company's Employee Stock Purchase Plan.

David L. Hoffman, General Counsel, CCO & Secretary of Delcath Systems, Inc., reports acquiring 20,161 shares of common stock through a transaction on March 19, 2024, including shares from the Employee Stock Purchase Plan.